Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03910296 · ClinicalTrials.gov registry record
Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 10
- Enrollment target
NCT03910296: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT03910296 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03910296 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The purpose of this research study is to develop a psychological treatment for patients with cancer, focused on the psychological symptoms they experience during opioid therapy.
Primary Outcome
Defined by participants' completion of 80% of measures
Interventions
- BEHAVIORAL Acceptance & Commitment Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-02-20 |
| Est. Completion | 2021-07-30 |
What the finished NCT03910296 record still lists
NCT03910296 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Acceptance & Commitment Therapy is the first listed.
NCT03910296 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03910296 about?
NCT03910296 is a clinical study titled "Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain". The purpose of this research study is to develop a psychological treatment for patients with cancer, focused on the psychological symptoms they experience during opioid therapy.
What is the current status of trial NCT03910296?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2019-02-20. Estimated completion is 2021-07-30.
What interventions are being tested in trial NCT03910296?
The interventions under investigation include: Acceptance & Commitment Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT03910296?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI